Band 7+: The chart below shows how much money five big pharmaceutical companies spent on research in 2012 and 2018 and gives an estimate of the amounts spent in 2022. Describe the data providing an overview of the general trends, reporting the main features, and making comparisons.

The bar chart illustrates the budget devoted to research among five large medicine producing organizations between 2012 and 2018 and predicts the sum for 2022.

Overall, the displayed data shows an increasing amount of money spent on research work by all companies. Predicted finance for research in 2022 generally exceeds the 2018 budget twice.

In 2012, all 5 industries spent less than ten billion dollars on research studies, and Pharm was the leading company by this criterion. After four years the distribution of money has increased – most companies, except Biopharm, have contributed more than 10 billion dollars to the field of research. Novas spent the largest share of money in 2018, while Biopharm dedicated the smallest part of the budget to research

The chart also demonstrates predicted data for 2022, which shows the rise of research budget in all pharmaceutical companies. Novas is expected to spend more than 50 billion dollars on research, which is almost twice as big as Fleming, which is about to spend around 30 billion dollars. Other companies will hypothetically use less than or around 25 billion dollars on research.